Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283359 | 1.00 | HCAR2 (0.69) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL5284814 | 1.00 | HCAR2 (0.69) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL22619937 | 0.92 | ATM (0.77) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL2946078 | 0.91 | HCAR2 (0.59) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL2946075 | 0.91 | HCAR2 (0.59) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL448454 | 0.91 | HCAR2 (0.82) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL448456 | 0.91 | HCAR2 (0.82) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL322228 | 0.91 | HCAR2 (0.82) | HCAR2ATMKEAP1NFE2L2MAPT | |
| SCHEMBL4934756 | 0.88 | HCAR2 (0.78) | HCAR2ATMKEAP1NFE2L2MAPT | |
| Hydrochloric Acid SCHEMBL28061109 | 0.88 | HCAR2 (0.78) | HCAR2ATMKEAP1NFE2L2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023123747-A1 | HYDROGEN ABSTRACTION PHOTOINITIATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州鹿山光电材料有限公司 | 2023-07-06 | — | — | WO | claimed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | claimed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | claimed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | claimed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| US-20180221284-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2018-08-09 | — | — | US | claimed |
| WO-2016182898-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2016-11-17 | — | — | WO | claimed |
| US-20150272894-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2015-10-01 | — | — | US | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | claimed |
| US-20120034303-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| US-20120034274-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| EP-2379062-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| EP-2379063-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| WO-2010079222-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| WO-2010079221-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| EP-1208135-B1 | IN-SITU PREPARATION OF POLYASPARTIC ESTER MIXTURE | BAYER AG (US) | 2003-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885ATM 2335/4885KEAP1 2571/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | HCAR2 1463/4885ATM 2607/4885KEAP1 2871/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885ATM 2335/4885KEAP1 2571/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | HCAR2 1463/4885ATM 2607/4885KEAP1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.